518 related articles for article (PubMed ID: 23645723)
1. Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: an uncommon but potentially severe disease.
Sivolella S; Lumachi F; Stellini E; Favero L
Anticancer Res; 2013 May; 33(5):1793-7. PubMed ID: 23645723
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.
Guarneri V; Miles D; Robert N; Diéras V; Glaspy J; Smith I; Thomssen C; Biganzoli L; Taran T; Conte P
Breast Cancer Res Treat; 2010 Jul; 122(1):181-8. PubMed ID: 20361252
[TBL] [Abstract][Full Text] [Related]
3. Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with/without bevacizumab.
Ngamphaiboon N; Frustino JL; Kossoff EB; Sullivan MA; O'Connor TL
Clin Breast Cancer; 2011 Aug; 11(4):252-7. PubMed ID: 21729657
[TBL] [Abstract][Full Text] [Related]
4. Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology.
Fusco V; Santini D; Armento G; Tonini G; Campisi G
Expert Opin Drug Saf; 2016 Jul; 15(7):925-35. PubMed ID: 27074901
[TBL] [Abstract][Full Text] [Related]
5. Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw.
Troeltzsch M; Woodlock T; Kriegelstein S; Steiner T; Messlinger K; Troeltzsch M
J Can Dent Assoc; 2012; 78():c85. PubMed ID: 22985897
[TBL] [Abstract][Full Text] [Related]
6. Antiresorptive drug-related osteonecrosis of the jaw.
Uyanne J; Calhoun CC; Le AD
Dent Clin North Am; 2014 Apr; 58(2):369-84. PubMed ID: 24655528
[TBL] [Abstract][Full Text] [Related]
7. New Non-Bisphosphonate Drugs that Produce Osteonecrosis of the Jaws.
Ramírez L; López-Pintor RM; Casañas E; Arriba Ld; Hernández G
Oral Health Prev Dent; 2015; 13(5):385-93. PubMed ID: 25884045
[TBL] [Abstract][Full Text] [Related]
8. Review of current literature and implications of RANKL inhibitors for oral health care providers.
Epstein MS; Ephros HD; Epstein JB
Oral Surg Oral Med Oral Pathol Oral Radiol; 2013 Dec; 116(6):e437-42. PubMed ID: 22901640
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab (Avastin): An anti-angiogenic drug associated with osteonecrosis of the jaw.
Wynn RL
Gen Dent; 2011; 59(6):410-3. PubMed ID: 22313910
[No Abstract] [Full Text] [Related]
10. The Role of Antiangiogenic Therapy in the Development of Osteonecrosis of the Jaw.
Fantasia JE
Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):547-53. PubMed ID: 26515736
[TBL] [Abstract][Full Text] [Related]
11. Osteonecrosis of the jaw after osteoporosis therapy with denosumab following long-term bisphosphonate therapy.
Rachner TD; Platzbecker U; Felsenberg D; Hofbauer LC
Mayo Clin Proc; 2013 Apr; 88(4):418-9. PubMed ID: 23541016
[TBL] [Abstract][Full Text] [Related]
12. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
[TBL] [Abstract][Full Text] [Related]
13. [Osteonecrosis of the jaw].
Drozdzowska B
Endokrynol Pol; 2011; 62 Suppl 3():4-9. PubMed ID: 22161980
[TBL] [Abstract][Full Text] [Related]
14. Osteonecrosis of the jaws and bevacizumab therapy: a case report.
Brunamonti Binello P; Bandelloni R; Labanca M; Buffoli B; Rezzani R; Rodella LF
Int J Immunopathol Pharmacol; 2012; 25(3):789-91. PubMed ID: 23058032
[TBL] [Abstract][Full Text] [Related]
15. Effect of antiresorptive drugs on bony turnover in the jaw: denosumab compared with bisphosphonates.
Ristow O; Gerngroß C; Schwaiger M; Hohlweg-Majert B; Kehl V; Jansen H; Hahnefeld L; Koerdt S; Otto S; Pautke C
Br J Oral Maxillofac Surg; 2014 Apr; 52(4):308-13. PubMed ID: 24582013
[TBL] [Abstract][Full Text] [Related]
16. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.
Dodson TB
Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):509-16. PubMed ID: 26362367
[TBL] [Abstract][Full Text] [Related]
17. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone.
Christodoulou C; Pervena A; Klouvas G; Galani E; Falagas ME; Tsakalos G; Visvikis A; Nikolakopoulou A; Acholos V; Karapanagiotidis G; Batziou E; Skarlos DV
Oncology; 2009; 76(3):209-11. PubMed ID: 19212145
[TBL] [Abstract][Full Text] [Related]
18. Osteonecrosis of the mandible associated with bevacizumab therapy.
Santos-Silva AR; Belizário Rosa GA; Castro Júnior Gd; Dias RB; Prado Ribeiro AC; Brandão TB
Oral Surg Oral Med Oral Pathol Oral Radiol; 2013 Jun; 115(6):e32-6. PubMed ID: 23567260
[TBL] [Abstract][Full Text] [Related]
19. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
20. Medication-Related Osteonecrosis of the Jaw: Basic and Translational Science Updates.
Allen MR
Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):497-508. PubMed ID: 26277349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]